The GLP-1 Revolution: Where Are We Now?
GLP-1 receptor agonists have become the fastest-growing drug class in pharmaceutical history. But the current market leaders (semaglutide, tirzepatide) are just the beginning. The pipeline is extraordinary.
Currently Approved
Semaglutide (Novo Nordisk)
- Injectable: Ozempic (diabetes), Wegovy (obesity)
- Oral: Rybelsus (diabetes), oral Wegovy in Phase III
- Weight loss: ~15% at 68 weeks
- Cardiovascular: SELECT trial — 20% MACE reduction
- Status: Market leader with broadest indication set
Tirzepatide (Eli Lilly)
- Injectable: Mounjaro (diabetes), Zepbound (obesity)
- Mechanism: Dual GIP/GLP-1 agonist
- Weight loss: ~22% at 72 weeks
- Status: Gaining market share; SURPASS-CVOT pending
Liraglutide (Novo Nordisk)
- Injectable: Victoza (diabetes), Saxenda (obesity)
- Weight loss: ~8% (less than semaglutide)
- Status: Being superseded by semaglutide
Phase III Pipeline
Retatrutide (Eli Lilly) — Triple Agonist
- Mechanism: GIP + GLP-1 + Glucagon receptor agonist
- Phase II weight loss: 24.2% at 48 weeks (unprecedented)
- TRIUMPH Phase III program: Ongoing
- Expected approval: 2026-2027
- Why it matters: Glucagon component adds thermogenesis and liver fat clearance
Orforglipron (Eli Lilly) — Oral Non-Peptide
- Mechanism: Oral small molecule GLP-1 agonist (not a peptide)
- Phase II weight loss: ~15% (comparable to injectable semaglutide)
- ACHIEVE Phase III program: Ongoing
- Why it matters: First oral GLP-1 agonist that could match injectable efficacy
Survodutide (Boehringer Ingelheim) — Dual Agonist
- Mechanism: GLP-1 + Glucagon dual agonist
- Phase II: 19% weight loss, dramatic liver fat reduction
- Focus: MASH (metabolic liver disease) — potential first-in-class
CagriSema (Novo Nordisk) — Combination
- Mechanism: Semaglutide + Cagrilintide (amylin analog)
- Phase II weight loss: 17.1% at 32 weeks
- REDEFINE Phase III program: Ongoing
- Why it matters: Adds amylin-mediated satiety to GLP-1 effects
Early Pipeline (Phase I/II)
| Compound | Company | Mechanism | Differentiator |
|----------|---------|-----------|----------------|
| Pemvidutide | Altimmune | GLP-1/Glucagon | Liver fat focus |
| VK2735 | Viking | GLP-1R agonist | Oral and injectable |
| AMG-133 | Amgen | GIP antagonist/GLP-1 agonist | Novel approach |
| Ecnoglutide | CSPC | Long-acting GLP-1 | Monthly dosing |
The Muscle Loss Problem
The elephant in the room: 30-40% of weight lost on GLP-1 agonists is lean mass. Next-generation approaches to address this:
- Bimagrumab + semaglutide: Anti-myostatin antibody to preserve muscle (trial ongoing)
- Exercise prescriptions: Resistance training mandatory alongside GLP-1 use
- Protein requirements: 1.2-1.6g/kg of goal body weight
What This Means for the Field
- Weight loss approaching surgery: Retatrutide at 24% rivals bariatric outcomes
- Oral options coming: Orforglipron could democratize access
- Beyond obesity: Alzheimer's (EVOKE trial), MASH, addiction, cardiovascular
- Combination era: CagriSema and bimagrumab combos push efficacy further
- Cost concerns: Current prices ($1000+/month) are a major barrier; generics and competition will drive costs down